ArticleClinical and experimental medicine2025
Identification of a fibroblast-derived gene signature reveals prognostic and therapeutic insights in pancreatic cancer.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative multimodal transcriptomics identifies a cancer-associated fibroblast membrane signature for predicting prognosis and therapeutic response in pancreatic ductal adenocarcinoma.Journal of molecular medicine (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Fibroblasts play a crucial role in the progression of pancreatic ductal adenocarcinoma (PDAC). This study aimed to develop a prognostic model based on fibroblast-specific gene signatures and identify key genes that may serve as therapeutic targets. Single-cell RNA sequencing data from PDAC and adjacent normal tissues were analyzed using high-dimensional weighted gene co-expression network analysis, and a prognostic signature was constructed using LASSO Cox regression and validated across multiple cohorts. Our findings revealed distinct fibroblast clusters enriched in PDAC and led to the development of a fibroblast-related prognostic signature comprising 14 key genes. The fibroblast-related risk score effectively stratified patients into high-risk and low-risk groups, revealing differences in immune cell infiltration, response to immune checkpoint blockade therapy, and sensitivity to chemotherapeutic drugs. This study presents a novel fibroblast-associated prognostic model with significant clinical utility in predicting PDAC patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.